Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IDEAYA Biosciences (IDYA) EBT: 2020-2025

Historic EBT for IDEAYA Biosciences (IDYA) over the last 4 years, with Sep 2025 value amounting to $108.5 million.

  • IDEAYA Biosciences' EBT rose 262.13% to $108.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$167.5 million, marking a year-over-year increase of 25.47%. This contributed to the annual value of -$327.0 million for FY2024, which is 143.23% down from last year.
  • Latest data reveals that IDEAYA Biosciences reported EBT of $108.5 million as of Q3 2025, which was up 175.24% from -$144.1 million recorded in Q4 2024.
  • In the past 5 years, IDEAYA Biosciences' EBT ranged from a high of $108.5 million in Q3 2025 and a low of -$144.1 million during Q4 2024.
  • Over the past 3 years, IDEAYA Biosciences' median EBT value was -$41.9 million (recorded in 2023), while the average stood at -$39.2 million.
  • In the last 5 years, IDEAYA Biosciences' EBT plummeted by 5,179.70% in 2023 and then skyrocketed by 262.13% in 2025.
  • IDEAYA Biosciences' EBT (Quarterly) stood at -$18.4 million in 2021, then slumped by 43.95% to -$26.4 million in 2022, then crashed by 58.52% to -$41.9 million in 2023, then slumped by 243.87% to -$144.1 million in 2024, then spiked by 262.13% to $108.5 million in 2025.
  • Its EBT stands at $108.5 million for Q3 2025, versus -$144.1 million for Q4 2024 and -$66.9 million for Q3 2024.